Opinion|Videos|September 10, 2024
Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS
Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For patients with higher-risk myelodysplastic syndromes (MDS), what are some of the primary challenges in conducting research and developing novel therapies for this patient population?
- How do social support and logistical factors, such as the ability to access clinics for extended periods for injectable hypomethylating agents (HMAs), affect treatment adherence and outcomes in patients with higher-risk MDS?
- Given that HMAs are the backbone of treatment for higher-risk MDS, how do oral options such as decitabine-cedazuridine and other emerging therapies address the need for more convenient administration while maintaining efficacy?
Advertisement
Related to this article
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
5